Rudolph Michael J, Muriuki Beatrice M, Chen Yang, Vance David J, Vorauer Clint, Piazza Carol Lyn, Freeman-Gallant Grace, Golonka Rachel M, Mirabile Gianna, Guttman Miklos, Cavacini Lisa A, Mantis Nicholas J
New York Structural Biology Center, New York, NY, United States.
Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States.
Front Immunol. 2025 Jul 7;16:1611828. doi: 10.3389/fimmu.2025.1611828. eCollection 2025.
During the course of Lyme disease, humans mount a robust and sustained antibody response against dozens of outer surface lipoproteins. Identifying which antibodies are associated with spirochete clearance and disease resolution is of paramount importance in therapeutic development. In this study, we describe the isolation and structural characterization of a human monoclonal antibody (MAb) against decorin binding protein A (DbpA), one of the most immunogenic of 's outer surface proteins. High-resolution epitope mapping by HDX-MS and X-ray crystallography revealed that F945 associates with a lateral face of DbpA in a side-on orientation without obstructing resides associated with DbpA's ability to bind components of the extracellular matrix. The structure of the DbpA-F945 Fab complex revealed an outsized role for variable light chain (V) germline encoded residues in mediating DbpA interactions. In fact, the majority of the critical contacts between F945 and DbpA involved V1-33 germline encoded residues, suggesting that certain human B cell receptors (BCR) may be preconfigured to recognize DbpA and therefore have a lower threshold for B cell activation and clonal development. Passive administration of F945 IgG was not sufficient to protect against in a mouse model of needle infection, although these experiments do not rule out a role for F945 in influencing tissue tropism and/or retention within specific niches. Nonetheless, it is tempting to speculate that F945 represents a class of DbpA antibodies with value in Lyme disease diagnostics, but that may not contribute to clearance or disease resolution in humans.
在莱姆病病程中,人体会针对数十种外表面脂蛋白产生强烈且持续的抗体反应。确定哪些抗体与螺旋体清除及疾病消退相关,在治疗研发中至关重要。在本研究中,我们描述了一种针对核心蛋白聚糖结合蛋白A(DbpA)的人单克隆抗体(MAb)的分离及结构表征,DbpA是莱姆病螺旋体外表面蛋白中免疫原性最强的蛋白之一。通过氢氘交换质谱(HDX-MS)和X射线晶体学进行的高分辨率表位作图显示,F945以侧对侧的方向与DbpA的一个侧面结合,且不妨碍与DbpA结合细胞外基质成分能力相关的位点。DbpA - F945 Fab复合物的结构揭示了可变轻链(V)种系编码残基在介导DbpA相互作用中发挥的重要作用。事实上,F945与DbpA之间的大多数关键接触涉及V1 - 33种系编码残基,这表明某些人B细胞受体(BCR)可能预先配置为可识别DbpA,因此B细胞激活和克隆发育的阈值较低。在针刺感染小鼠模型中,被动给予F945 IgG不足以预防莱姆病螺旋体感染,尽管这些实验并未排除F945在影响莱姆病螺旋体组织嗜性和/或在特定生态位内滞留方面的作用。尽管如此,很诱人推测F945代表一类在莱姆病诊断中有价值的DbpA抗体,但可能对人体中莱姆病螺旋体的清除或疾病消退没有作用。